CytomX Therapeutics (CTMX) Current Leases (2019 - 2026)

CytomX Therapeutics has reported Current Leases for 8 years, with the latest figure at $2.9 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases fell 46.04% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.9 million (down 46.04% YoY), and the FY2025 full-year result was $4.2 million, down 17.59% from the prior year.
• Current Leases for Q1 2026 stood at $2.9 million, down from $4.2 million in the prior quarter.
• The five-year high for Current Leases was $5.6 million in Q3 2025, with the low at $2.9 million in Q1 2026.
• Historically, Current Leases has averaged $4.5 million across 5 years, with a median of $4.5 million in 2023.
• Annual changes were most pronounced in 2022 — Current Leases climbed 12.82% — and 2026, when it tumbled 46.04%.
• CytomX Therapeutics' Current Leases stood at $4.1 million in 2022, then advanced by 12.42% to $4.6 million in 2023, then grew by 12.12% to $5.1 million in 2024, then slipped by 17.59% to $4.2 million in 2025, then sank by 32.64% to $2.9 million in 2026.
• The last three Current Leases figures came in at $2.9 million (Q1 2026), $4.2 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.